Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed COO
Appointed director
BridgeBio Pharma, Inc. (BBIO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update - Announced consistently positive results from the Phase 3 ATTRibute-CM study of acoramidis in patients with transthyretin amyloid cardiomyopathy , including a highly statistically significant result observed on the primary endpoint with a Win Ratio of 1.8 , demonstrating a continued potentially best-in-class efficacy and well-tolerated safety profile, and a mean increase in annualized height velocity of 3.38cm/year with no treatment-related adverse events - Dosed the first participant in FORTIFY, a global Phase 3 study of BBP-418 in patients with limb girdle muscular dystrophy type 2I/R9 and met with the FDA to discuss the use of glycosylated alpha-dystroglycan levels as a surrogate endpoint; based on this ..."
02/23/2023 8-K Quarterly results, Appointed a new director
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update"
08/04/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "BridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business Update"
08/13/2021 8-K Quarterly results
05/14/2021 8-K Quarterly results
02/26/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "BridgeBio Pharma, Inc. Reports Third Quarter 2020 Financial Results And Business Update"
08/11/2020 8-K Quarterly results
05/13/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 13, 2020 BridgeBio Pharma, Inc. Delaware 001-38959 84-1850815 421 Kipling Street Palo Alto, CA 94301 391-9740 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Ex...",
"BridgeBio Pharma, Inc. Reports First Quarter 2020 Financial Results and Business Update"
12/26/2019 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy